Newton Biocapital enters as new investor, strong participation of existing investors Pivotal Phase 2b trial initiation in 2027 of BIOX-101 to treat intracerebral hemorrhage BIOX-101 may be ...

Bioceres reported 1Q26 results with continued revenue declines but improved gross margins and significant OpEx reductions, boosting profitability. BIOX faces severe financial risks, including default ...

Bioceres Crop Solutions Corp (BIOX) reported its first-quarter 2025 earnings, revealing a significant miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.1183 ...

Bioceres Crop (BIOX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.09 per share a year ago. These figures are ...

Gross profit remained stable at $36 million despite a drop in revenues, with a gross margin expansion of 650 basis points. Significant improvements in operating profits and adjusted EBITDA due to cost ...

An announcement from Bioceres Crop Solutions ( (BIOX)) is now available. On November 10, 2025, Bioceres Crop Solutions received an Acceleration Notice from its noteholders, alleging defaults under its ...

Fintel reports that on November 14, 2025, Canaccord Genuity maintained coverage of Bioceres Crop Solutions (NasdaqGS:BIOX) with a Hold recommendation. As of November 9, 2025, the average one-year ...

Bioceres Crop Solutions ( (BIOX)) just unveiled an announcement. On November 5, 2025, Bioceres Crop Solutions Corp. announced the appointment of Mr. Simon Vumbaca to its Board of Directors and Mr.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Bioxodes has appointed Dr Philippe Montyene as chairman of its Board of Directors. The news comes as Bioxodes releases positive interim phase 2a data for its lead candidate, BIOX-101, in the treatment ...